Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D G Decker

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Mayo Clinic Proceedings|September 1, 1972
Clear-cell adenocarcinoma of the cervix after maternal treatment with synthetic estrogensK L Noller, D G Decker, A P Lanier, et al.
Cancer Chemotherapy Reports|April 1, 1973
6-Dehydro-6,17 alpha-dimethylprogesterone (NSC-123018) for the treatment of metastatic and recurrent ovarian carcinomaG D Malkasian, D G Decker, E O Jorgensen, et al.
Cancer Treatment Reports|November 1, 1981
Concomitant phase II studies of pyrazofurin and razoxane in alkylating agent-resistant cases of epithelial ovarian carcinomaJ H Edmonson, D G Decker, G D Malkasian, et al.
American Journal of Obstetrics and Gynecology|February 15, 1974
Evaluation of 6,17 alpha-dimethyl-6-dehydroprogesterone for treatment of recurrent and metastatic gynecologic malignancyG D Malkasian, D G Decker, E O Jorgensen, et al.
Cancer|February 1, 1979
Ovarian cancer: incidence and case-control studyJ F Annegers, H Strom, D G Decker, et al.
Minnesota Medicine|February 1, 1974
Mesonephric carcinoma of cervix. A case associated with intra-uterine pregnancyK L Noller, R S Sheldon, R A Lee, et al.
Gynecologic Oncology|February 1, 1978
Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agentsJ H Edmonson, D G Decker, G D Malkasian, et al.
Journal of the National Cancer Institute|December 1, 1977
Phase II evaluation of cytembena (NSC-104801) in patients with advanced ovarian carcinoma resistant to alkylating agents: brief communicationJ H Edmonson, D G Decker, G D Malkasian, et al.
American Journal of Obstetrics and Gynecology|February 1, 1976
Clear-cell adenocarcinoma of the vagina and cervix: survival dataK L Noller, D G Decker, R E Symmonds, et al.
Mayo Clinic Proceedings|November 1, 1973
Cancer and stilbestrol. A follow-up of 1,719 persons exposed to estrogens in utero and born 1943-1959A P Lanier, K L Noller, D G Decker, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Mayo Clinic Proceedings|September 1, 1972
Clear-cell adenocarcinoma of the cervix after maternal treatment with synthetic estrogensK L Noller, D G Decker, A P Lanier, et al.
Cancer Chemotherapy Reports|April 1, 1973
6-Dehydro-6,17 alpha-dimethylprogesterone (NSC-123018) for the treatment of metastatic and recurrent ovarian carcinomaG D Malkasian, D G Decker, E O Jorgensen, et al.
Cancer Treatment Reports|November 1, 1981
Concomitant phase II studies of pyrazofurin and razoxane in alkylating agent-resistant cases of epithelial ovarian carcinomaJ H Edmonson, D G Decker, G D Malkasian, et al.
American Journal of Obstetrics and Gynecology|February 15, 1974
Evaluation of 6,17 alpha-dimethyl-6-dehydroprogesterone for treatment of recurrent and metastatic gynecologic malignancyG D Malkasian, D G Decker, E O Jorgensen, et al.
Cancer|February 1, 1979
Ovarian cancer: incidence and case-control studyJ F Annegers, H Strom, D G Decker, et al.
Minnesota Medicine|February 1, 1974
Mesonephric carcinoma of cervix. A case associated with intra-uterine pregnancyK L Noller, R S Sheldon, R A Lee, et al.
Gynecologic Oncology|February 1, 1978
Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agentsJ H Edmonson, D G Decker, G D Malkasian, et al.
Journal of the National Cancer Institute|December 1, 1977
Phase II evaluation of cytembena (NSC-104801) in patients with advanced ovarian carcinoma resistant to alkylating agents: brief communicationJ H Edmonson, D G Decker, G D Malkasian, et al.
American Journal of Obstetrics and Gynecology|February 1, 1976
Clear-cell adenocarcinoma of the vagina and cervix: survival dataK L Noller, D G Decker, R E Symmonds, et al.
Mayo Clinic Proceedings|November 1, 1973
Cancer and stilbestrol. A follow-up of 1,719 persons exposed to estrogens in utero and born 1943-1959A P Lanier, K L Noller, D G Decker, et al.
Pageof 5